Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade

Abstract Treatment with immune checkpoint inhibitors has altered the course of malignant melanoma, with approximately half of the patients with advanced disease surviving for more than 5 years after diagnosis. Currently, there are no biomarker methods for predicting outcome from immunotherapy. Here,...

Full description

Bibliographic Details

Published in:	npj Precision Oncology
Main Authors:	Ioannis A. Vathiotis, Leonidas Salichos, Sandra Martinez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-12-01
Online Access:	https://doi.org/10.1038/s41698-022-00330-3